4 Firms Spearhead $1.2B Catalent-Paragon Bioservices Deal
Drug development and delivery company Catalent on Monday agreed to buy private equity-backed Paragon Bioservices Inc. for $1.2 billion, in a deal steered by Fried Frank, Kirkland, Gordon Feinblatt and Latham....To view the full article, register now.
Already a subscriber? Click here to view full article